Tandem transplantation in lymphoma

K. P. Papadopoulos, W. Noguera-Irizarry, C. S. Hesdorffer

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

Original languageEnglish (US)
Pages (from-to)529-535
Number of pages7
JournalBone marrow transplantation
Issue number6
StatePublished - 2001
Externally publishedYes


  • Allogeneic
  • Autologous
  • Lymphoma
  • Tandem transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Tandem transplantation in lymphoma'. Together they form a unique fingerprint.

Cite this